NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

抗肥胖藥的全球市場:成長,趨勢,預測(2019∼2024年)

Anti-obesity Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 391328
出版日期 內容資訊 英文 118 Pages
商品交期: 2-3個工作天內
價格
抗肥胖藥的全球市場:成長,趨勢,預測(2019∼2024年) Anti-obesity Drugs Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年08月01日內容資訊: 英文 118 Pages
簡介

全球抗肥胖藥市場,隨著美國FDA和歐洲EMA的認證數增加,而穩定成長。從2012年到2016年,許多製藥公司在臨床實驗上進行了高額的投資。

本報告提供全球抗肥胖藥市場相關調查,市場趨勢與各市場區隔趨勢,各地區預測,加入此市場的主要企業的簡介等相關資訊彙整。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 市場定義趨勢

  • 市場概要
  • 推動市場的要素
    • 肥胖罹患率上升
    • 久坐的生活習慣
  • 阻礙市場的要素
    • 替代治療方法的取得
    • 藥物的副作用
    • 藥物開發成本高
  • 產業的魅力度:波特五力分析

第5章 市場區隔

  • 各作用機制
    • 外周作用抗肥胖藥
    • 中樞作用性抗肥胖藥
  • 各藥物
    • 處方藥
    • OTC藥
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東、非洲
    • 南美

第6章 競爭環境

  • 企業簡介
    • Arena Pharmaceuticals
    • GlaxoSmithKline
    • Nalpropion Pharmaceuticals Inc.
    • F Hoffmann-La Roche
    • Vivus
    • Bayer AG
    • Novo Nordisk
    • Pfizer
    • Eisai

第7章 市場機會與未來趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 53633

The anti-obesity drugs market is growing steadily, with gradual growth in the number of approvals from the US FDA and Europe. However, there are very few drugs in the late stage of development.

Moreover, increasing obesity rates, globally, are leading to increasing the demand for anti-obesity drugs. Health risks from obesity cause death of 2.8 million people, globally, every year, as per the World Health Organization 2017 data. The increasing obese population is primarily due to the increase in unhealthy eating habits and a sedentary lifestyle. These factors have increased the demand for anti-obesity drugs.

However, the availability of more effective alternative therapies and treatments and potential side-effects of anti-obesity drugs are expected to restraint market growth.

Key Market Trends

OTC Drugs Segment is Expected to Exhibit a Fastest Growth Rate over the Forecast Period

  • Currently, obesity is a major concern, globally. The rising intake of junk foods/fast foods is resulting in declining health among the population, worldwide. As mentioned earlier, obesity is one of the most prevalent problems faced by people of this century, especially in some developed parts of the world. For instance, in the United States, from 1999-2000 to 2017-2018, the prevalence of obesity increased from 30.5% to 42.4%, and the prevalence of severe obesity increased from 4.7% to 9.2%, as per the 2018 report by the Centers for Disease Control and Prevention.
  • In most countries, Orlistat is marketed as a prescription drug under the trade name Xenical, by Roche, while it is sold as an OTC drug under the trade name Alli, by GlaxoSmithKline, in the United Kingdom and the United States. The cost-effectiveness and ease of availability of OTC products are expected to propel the growth of the market studied.

North America is Expected to Dominate the Market over the Forecast Period

  • North America dominated the global anti-obesity drugs market, with the United States accounted as the major contributor to the market. The primary factors driving the growth of the market studied are an increase in the obese population and high healthcare spending.
  • The United States (38.2%) has the highest percentage of the obese population in the world, followed closely by Mexico (32.4%), as per 2017 statistics by OECD. As per the report, Canada had 25.8% of people who were obese. The high obesity rate is another factor for the high demand for anti-obesity drugs in the region. Therefore, these factors have positively affected the market growth in the region.

Competitive Landscape

The presence of major market players, such as GlaxoSmithKline PLC, Novo Nordisk AS, Pfizer Inc., F Hoffmann-La Roche AG, and Bayer AG, is increasing the overall competitive rivalry of the market. Large organizations rely heavily on advertising expenses and branding strategies, collaborating with successful personality, initiative, or programs at the national levels, which promote their product. Therefore, these are recognized earlier than other brands in the market studied. With the high prevalence rate of the disease, the intensity of competitive rivalry is moderate to high.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Burden of Obesity and Related Chronic Diseases
    • 4.2.2 Growing Unhealthy and Sedentary Lifestyle
  • 4.3 Market Restraints
    • 4.3.1 Availability of Alternative Treatment Options
    • 4.3.2 Side Effect of Drugs
  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Mechanism of Action
    • 5.1.1 Peripherally Acting Drugs
    • 5.1.2 Centrally Acting Drugs
  • 5.2 By Drug Type
    • 5.2.1 Prescription Drugs
    • 5.2.2 OTC Drugs
  • 5.3 By Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 United Kingdom
      • 5.3.2.2 Germany
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Bayer AG
    • 6.1.2 Currax Pharmaceuticals LLC
    • 6.1.3 F Hoffmann-La Roche AG
    • 6.1.4 GlaxoSmithKline PLC
    • 6.1.5 Novo Nordisk AS
    • 6.1.6 Pfizer Inc.
    • 6.1.7 Vivus

7 MARKET OPPORTUNITIES AND FUTURE TRENDS